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Androgen deprivation therapy (ADT) of androgen-dependent prostate cancer (PCa), which is still the gold standard treatment, was
based Huggins and Hodges' 1941 ﬁnding that the growth of PCa cells requires the androgen, testosterone (Rick & Schally, 2015). In addition, an
increasing body of evidence has revealed that the development and progression of androgen-dependent PCa to castration-resistant prostate
cancer (CRPC) have an intimate association with the androgen–
androgen receptor axis (AR axis) (Knudsen & Scher, 2009). The application of AR axis drugs, such as the 5α-reductase inhibitors (5ARI), ﬁnasteride and dutasteride, which decrease levels of dihydrotestosterone
(DHT) in order to prevent development or progression of PCa, remains
to be extensively discussed and is controversial (Kosaka et al., 2014).
The concept is driven by the results of two large, randomized,
placebo-controlled trials: the Prostate Cancer Prevention Trial (PCPT)
with ﬁnasteride (Thompson et al., 2003) and the Reduction by
Dutasteride of Prostate Cancer Events (REDUCE) trial (Andriole et al.,
2010). In the PCPT, ﬁnasteride signiﬁcantly reduced the overall risk of
prostate cancer but cancers with high Gleason scores (7–10) were
found in 6.4% of the tumors in the ﬁnasteride group, compared with
only 5.1% of those being found in the placebo group.
DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.03.047.
⁎ Corresponding author at: Research Service (151), Veterans Affairs Medical Center,
1201 N.W. 16th Street, Miami, FL 33125, USA.
E-mail address: ferencrick@gmail.com (F.G. Rick).

In a manner analogous to the PCPT trial, the REDUCE trial reported
an overall reduction in the number of PCa patients (with a low Gleason
score of 5–6) in those receiving dutasteride versus those given a placebo
(19.9% and 25.1%, respectively); similarly, tumors with a high Gleason
score (8–10) were more frequent in the dutasteride-treated group
than in the placebo group. In the Reduction by Dutasteride of Clinical
Progression Events in Expectant Management (REDEEM) trial,
dutasteride was associated with a 38% decrease in the cancer detection
rate on repeat biopsy at year 3 in men with low-grade Gleason score (5–
6) prostate cancer undergoing active surveillance and who received
three years of treatment with dutasteride or placebo (Fleshner et al.,
2012).
Because of concerns regarding the possible induction of de novo aggressive PCa, the US Food and Drug Administration did not grant approval of 5ARIs for the chemoprevention of PCa in December 2010
(Theoret et al., 2011). However, it is still unclear whether the observed
increase in high-grade CaP in these trials was real or artifact (Lucia et al.,
2007). These observations cannot be fully explained from a purely
mechanistic point of view. Therefore, further basic and clinical investigations are necessary (Kosaka et al., 2014).
In this issue of EBioMedicine, Kim et al. seek to improve biologic understanding of the grade-speciﬁc effects of the 5ARI, ﬁnasteride, by
studying 183 men with localized prostate cancer, who were randomized to receive 5 mg of ﬁnasteride or placebo daily for 4 to 6 weeks
pre-prostatectomy (Kim et al., 2016). In fact, this is one of the few studies done in early prostate cancer to investigate the time it takes for
changes in gene expression to occur following ﬁnasteride therapy. The
primary end point was to compare the frequency of expression of a
predeﬁned high-grade molecular signature (ERβ, UBE2C, SRD5A2, and
VEGF) differentiating high- and low-grade tumors in the Gleason
grade (GG) 3 areas of ﬁnasteride-exposed tumors with those of
placebo-exposed tumors, adjusted for Gleason score (GS) at prostatectomy. Secondary endpoints included assessment of androgen receptor
(AR) levels, Ki-67, and cleaved caspase 3 to estimate the effects of ﬁnasteride on the expression of its downstream targets, cell proliferation,
and apoptosis, respectively. Unfortunately, the primary endpoint could
not be assessed as the predetermined molecular signature was not
able to distinguish GG3 from GG4 areas in the placebo group.
However, expression of AR was signiﬁcantly lower in the GG4 areas
of the ﬁnasteride group compared to those of the placebo group (Kim et
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al., 2016). The authors claim that this ﬁnding is in accord with an emerging concept that reduced androgens in prostate tissues may, over time,
lead to de-repression of AR expression, which, in turn, deregulates AR
function and downstream de-repression of the AR target genes normally suppressed by androgens (Kim et al., 2016). Within the ﬁnasteride
group, AR expression was also lower in GG4 than in GG3 areas, but
not signiﬁcantly.
Expression of the apoptosis marker, cleaved caspase 3, in GG3 and
GG4 tumor areas was signiﬁcantly increased after short-term exposure
to ﬁnasteride, consistent with preventive efﬁcacy, as shown in the PCPT,
and was lower in GG4 than in GG3 areas within both treatment and placebo groups (Kim et al., 2016). In the literature, conﬂicting ﬁndings on
the inﬂuence of 5ARIs have been reported, nonetheless, it seems that
the molecular effects of 5ARIs depend on the exposure duration.
One major limitation of this trial is the short period over which the
study was conducted: molecular alterations in tumors exposed to ﬁnasteride may occur over a longer period of time than 4–6 weeks. Another
possible explanation is that the study was underpowered: the original
projections of 100 patients for each group may have been inadequate.
In addition, the evaluation of tumor samples was restricted to the peripheral zone and to samples with GG patterns primarily presenting
poorly formed and fused glands. It is not known what changes occur
in tumors of transition zone origin or other GG4 patterns.
In summary, this overall well-designed trial by Kim et al. emphasizes
the necessity for further investigation of time-based effects of ﬁnasteride on molecular changes and their basic and clinical importance. Conﬁrmation and extension of these ﬁndings may result in a valuable test

allowing the identiﬁcation of ﬁnasteride-responsive tumors in order
to provide personalized care and/or in improved estimates of the risk
of progression of the individual's disease.
Disclosure
The authors declared no conﬂicts of interest relevant to this
manuscript.
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